The opinion in support of the decision being entered today was not written
for publication and is not binding precedent of the Board.
UNITED STATES PATENT AND TRADEMARK OFFICE
__________
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
__________
Ex parte SOPHIE CHEN
__________
Appeal No. 2006-3290
Application No. 10/072,823
__________
ON BRIEF
__________
Before SCHEINER, ADAMS and GRIMES, Administrative Patent Judges.
ADAMS, Administrative Patent Judge.
DECISION ON APPEAL
This is a decision on the appeal under 35 U.S.C. § 134 from Examiner’s
final rejection of claims 1-9, 11-16, 18-23, 26-29 and 32-35, which are all the
claims pending in the application.
Claim 11 is illustrative of the subject matter on appeal and is reproduced
below:
1. A composition for treating or preventing prostate cancer or breast
cancer [comprising]:
oridonin, a pharmaceutically acceptable salt or ester of oridonin, a
selectively substituted analog of oridonin, or a combination thereof;
and
lupulone, a pharmaceutically acceptable salt or ester of lupulone, a
selectively substituted analog of lupulone, or a combination thereof;
wherein the composition is suitable for the treatment or prevention
of prostate cancer or breast cancer.
1 The remaining claims depend directly or indirectly from claim 1.
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: September 9, 2013